Fig 5. Reactivity of T cell epitopes induced by the pRhPD1-p27 vaccine during SHIV_SF162P3CN challenge.

(A) T cell responses against the PD1-based vaccine-induced CD8⁺ and (B) CD4⁺ T cell epitopes at 17 weeks after SHIV_SF162P3CN challenge. (C) T cell epitope profiles on Gag-p27 of vaccinated macaques in Group B after SHIV_SF162P3CN challenge. (D) Long-term pVL monitoring in the vaccinated/challenged macaques from Group A. Anti-CD8β antibody (clone CD8b255R1) was infused into these vaccinated macaques intravenously at 17 weeks post-challenge, after confirming pVL had reduced to undetectable levels. At 103 weeks post-SHIV_SF162P3CN challenge, these macaques also received a boost immunisation of the pRhPD1-p27 vaccine via i.m./EP. (E) Frequencies of CD8⁺ and (F) CD4⁺ T cells specific to Gag-p27 and Nef antigens 3 weeks after pRhPD1-p27 re-immunization. Means ± SEM are shown.